Verition Fund Management
DRNA

Verition Fund Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Verition Fund Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-56,587
Closed -$1.25M – 1172
2019
Q4 		$1.25M Sell
56,587
-50,558
-47% -$1.02M 0.02% 381
2019
Q3 		$1.54M Buy
+107,145
New +$1.53M 0.04% 304
2018
Q2 		– Sell
-14,704
Closed -$141K – 1424
2018
Q1 		$141K Buy
+14,704
New +$159K 0.01% 1040

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Verition Fund Management's DRNA Position: Q1 2020 in Review

Verition Fund Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2020, closing a stake of 56,587 shares — an estimated $1.25M sold.

Verition Fund Management first reported a position in DRNA in Q1 2018 and held it in 3 quarters. The position peaked at $1.54M in Q3 2019. 144 funds tracked by Wall St. Rank hold DRNA as of Q1 2020.

  • Verition Fund Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Verition Fund Management sold 56,587 Dicerna Pharmaceuticals, Inc. shares in Q1 2020, an estimated $1.25M.
  • Verition Fund Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2018 and held it in 3 quarters.
  • Verition Fund Management's Dicerna Pharmaceuticals, Inc. position peaked at $1.54M in Q3 2019.
  • 144 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2020.

Based on Verition Fund Management's 13F filing for Q1 2020, filed 15 May 2020.